Table 4 the sensitivity of patients to anti-tumor agents
Compounds | Total patients | Patients were sensitive to compounds | |
|---|---|---|---|
IC max group | IC 50 group | ||
5-FU | 26 | – | – |
PAC | 26 | – | – |
CDDP | 26 | 8 | 3 |
EPI | 26 | 9 | 4 |
L-OHP | 26 | 5 | 2 |
Compounds | Total patients | Patients were sensitive to compounds | |
|---|---|---|---|
IC max group | IC 50 group | ||
5-FU | 26 | – | – |
PAC | 26 | – | – |
CDDP | 26 | 8 | 3 |
EPI | 26 | 9 | 4 |
L-OHP | 26 | 5 | 2 |